You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA29
  • Published:  26 September 2001
  • Guidance
  • Tools and resources
  • Information for the public
  • History

TA29 Leukaemia (lymphocytic) - fludarabine: Appendix A - decision paper presented to the Institute's Guidance Executive

TA29 Leukaemia (lymphocytic) - fludarabine: Appendix A - decision paper presented to the Institute's Guidance Executive TA29 Leukaemia (lymphocytic) - fludarabine: Appendix A - decision paper presented to the Institute's Guidance Executive
20 December 2013
(106.41 Kb 30 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 18 December 2013

Back to top